Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lysoclear
- Development stage
- Preclinical
- Lead developer
- Ichor Life Sciences
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
Lysoclear is a recombinant enzyme therapy being developed by Ichor Therapeutics, through its portfolio company Lysoclear, Inc., for the treatment of atrophic (dry) age-related macular degeneration (AMD) and Stargardt's macular degeneration. The therapy is designed to clear toxic vitamin A aggregates, such as N-retinylidene-N-retinylethanolamine (A2E) and other lipofuscin components, from the lysosomal compartments of retinal pigmented epithelial (RPE) cells. By degrading these metabolic byproducts, Lysoclear aims to restore lysosomal function and prevent the progressive RPE cell death and subsequent vision loss characteristic of these macular dystrophies. The program is currently in the preclinical stage of development.
- Brand names
- Lysoclear
02
Targets
A2ELipofuscin
Beyond the preview
Go deeper on Lysoclear.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lysoclear.